Trending...
- Sea Tales Strengthens U.S. Leadership Team as Retail Expansion Accelerates
- Patented Foodservice Products Company with Strong Gross Margins and Substantial Two-Year Revenue Growth Hits Market for $1.6 Million
- Amaris Mint® Confirms UK Availability of Swedish-Made BioBoost Daily Nutrition Range
PHILADELPHIA, June 18, 2021 /PRNewswire/ -- It's long been known that people living with HIV experience a loss of white matter in their brains. As opposed to gray matter, which is composed of the cell bodies of neurons, white matter is made up of cells that produce myelin, a fatty substance that coats neurons, offering protection and helping them transmit signals efficiently. A reduction in white matter is associated with motor and cognitive impairment.
Earlier work by a team from Penn Dental Medicine and Children's Hospital of Philadelphia (CHOP) found that antiretroviral therapy (ART)—the lifesaving drugs that many with HIV use daily—can reduce white matter, but it wasn't clear how the virus itself contributed to this loss.
In a new study using both human and rodent cells, the team has determined how HIV prevents the myelin-making brain cells called oligodendrocytes from maturing, reducing white matter production. When the researchers applied a compound blocking to this process, the cells were once again able to mature. The work appears in the journal Glia.
More on The PennZone
"Even when people with HIV have their disease well-controlled by antiretrovirals, they still have the virus present in their bodies, so this study came out of our interest in understanding how HIV infection itself affects white matter," says Kelly Jordan-Sciutto, professor at Penn Dental Medicine and the study's co-senior author. "By understanding those mechanisms, we can take the next step to protect people with HIV from these impacts."
Jordan-Sciutto and Judith Grinspan, CHOP research scientist and Professor of Neurology at Penn Medicine, have been collaborating to elucidate how ART and HIV affect the brain. Their previous work on antiretrovirals had shown that commonly used drugs disrupted the function of oligodendrocytes, reducing myelin formation.
More on The PennZone
In the current study, they aimed to isolate the effect of HIV on this process by looking at human macrophages, one of the major cell types that HIV infects.
Ultimately, the researchers want to discern the effects of the virus from the drugs used to treat it in order to better evaluate the risks of each.
"When we put people on ART, it's important to understand the implications," says Jordan-Sciutto. "Antiretrovirals may prevent the establishment of a viral reservoir in the central nervous system, which would be wonderful, but we also know some drugs have unintended consequences, which may include altering white matter." Read more on the study >>
Contact: Beth Adams, [email protected]
SOURCE Penn Dental Medicine
Related Links
http://www.dental.upenn.edu
Earlier work by a team from Penn Dental Medicine and Children's Hospital of Philadelphia (CHOP) found that antiretroviral therapy (ART)—the lifesaving drugs that many with HIV use daily—can reduce white matter, but it wasn't clear how the virus itself contributed to this loss.
In a new study using both human and rodent cells, the team has determined how HIV prevents the myelin-making brain cells called oligodendrocytes from maturing, reducing white matter production. When the researchers applied a compound blocking to this process, the cells were once again able to mature. The work appears in the journal Glia.
More on The PennZone
- Shelter Structures America makes European debut at TEMPOR EXPO 2026 in Fulda, Germany
- The Culture and Travel Report Enters a New Chapter as Travel and Hospitality Brands Take Notice
- Regcrest LLC Publishes Free 50-State Tax Account Closure Checklist Tool
- HydroExcavation.com Relaunches With Exclusive Local Service Areas and Dedicated Hydrovac Manufacturer Directory
- Sky Quarry Enters a Powerful New Chapter: Refinery Restart Emminent, Nevada Oil Initiative and Visibility Put (NAS DAQ: SKYQ) in the Spotlight
"Even when people with HIV have their disease well-controlled by antiretrovirals, they still have the virus present in their bodies, so this study came out of our interest in understanding how HIV infection itself affects white matter," says Kelly Jordan-Sciutto, professor at Penn Dental Medicine and the study's co-senior author. "By understanding those mechanisms, we can take the next step to protect people with HIV from these impacts."
Jordan-Sciutto and Judith Grinspan, CHOP research scientist and Professor of Neurology at Penn Medicine, have been collaborating to elucidate how ART and HIV affect the brain. Their previous work on antiretrovirals had shown that commonly used drugs disrupted the function of oligodendrocytes, reducing myelin formation.
More on The PennZone
- OneVizion Launches Vera AI, Bringing Connected Operational Context to Infrastructure Teams
- P-Wave Press Announces Pushing the Wave 2025 by L.A. Davenport
- DONGSHENG Titanium Recycling: Promoting a Closed-Loop Cycle for High-End Titanium Materials
- French Camp Academy Releases New Video Inviting Individuals to Consider a Life of Service
- LET US READ Documentary on Dyslexia and Literacy to Screen at TCL Chinese 6 in Hollywood
In the current study, they aimed to isolate the effect of HIV on this process by looking at human macrophages, one of the major cell types that HIV infects.
Ultimately, the researchers want to discern the effects of the virus from the drugs used to treat it in order to better evaluate the risks of each.
"When we put people on ART, it's important to understand the implications," says Jordan-Sciutto. "Antiretrovirals may prevent the establishment of a viral reservoir in the central nervous system, which would be wonderful, but we also know some drugs have unintended consequences, which may include altering white matter." Read more on the study >>
Contact: Beth Adams, [email protected]
SOURCE Penn Dental Medicine
Related Links
http://www.dental.upenn.edu
0 Comments
Latest on The PennZone
- Amaris Mint® Confirms UK Availability of Swedish-Made BioBoost Daily Nutrition Range
- Sea Tales Strengthens U.S. Leadership Team as Retail Expansion Accelerates
- Patented Foodservice Products Company with Strong Gross Margins and Substantial Two-Year Revenue Growth Hits Market for $1.6 Million
- Little Yellow Bungalow is an independent fashion and lifestyle brand founded by Denise Laudadio
- Robert DeMaio, Phinge CEO to Speak at 30th IIPLA 2026 on Securing IP, User Data & Digital Sovereignty via Verified App-less Tech. Attend the Live Q&A!
- Dividend Stacker Launches Free Calendar and Alerts for High-Yield ETF Payouts
- Paul Ohana - From Beverly Hills Salon Chair To Beauty Founder Celebrity Hair Expert
- ChargeOn Announces Conversational Payment Management Solution
- King Larry Steps Into His Moment With Music, Major Performances and a Story Built on Persistence
- Church Tradition Takes an Unexpected Turn at the Ford Community & Performing Arts Center
- SHI Introduces the RP-222B3S, Its Highest-Capacity 4K Pulse Tube Cryocooler
- Redefining Proactive Care: The Rise of the Hybrid Concierge Medical Model
- As Canada and America Turn on Each Other, These Two Authors Stay On Speaking Terms
- Benny Turner Revisits Freddie King's Legacy for 50th Anniversary of His Passing
- GitKraken Names Jim Shaw CEO as Software Teams Move From AI Adoption to Multi-Agent Orchestration
- Brévant Guide Launches New National Restaurant Guide Across Canada
- Free JavaScript Charting Library ProEssentialsJS Permits Commercial Use. Highcharts, SciChart and LightningChart Free Tiers Do Not
- Mito Health Passes One Million Lab Tests, Expands to Seven Categories of Preventive Health Testing
- VC Fast Pitch and Steamwork Ventures Bring Startup & Investor Networking Event to Santa Barbara on October 8
- Volant Announces Major Partnership with the STEM Racing Canada Program to CHAMPION YOUTH ENGINEERING